Company news

Verrica Pharmaceuticals Inc. news in 2024

Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2024, newest first.

View company

Verrica Provides Business and Operational Update

December 19, 2024

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 8, 2024

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

December 5, 2024

Verrica Announces Pricing of $42.0 Million Public Offering

November 20, 2024

Verrica Announces Proposed Public Offering

November 19, 2024

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

November 3, 2024

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

October 23, 2024

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

October 1, 2024

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 13, 2024

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

August 13, 2024

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

June 30, 2024

Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

May 14, 2024

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

May 12, 2024

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

March 25, 2024

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

February 28, 2024

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

February 21, 2024

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

January 28, 2024

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

January 4, 2024

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

January 3, 2024

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

January 2, 2024

Calls in 2024

Decks in 2024